Document:

EXECUTIVE
EMPLOYMENT AGREEMENT

 

THIS
EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), by and between Landstar, Inc. a Nevada corporation
through its operating subsidiary, Data443 Risk Mitigation, Inc., a North Carolina corporation (collectively, the “Company”),
and Steven C. Dawson (“Employee”) (collectively referred to as the “Parties”), is
entered into this 30th day of April 2019, effective as of 1st of May 2019 (the “Effective Date”).

 

WITNESSETH

 

WHEREAS,
the Company is engaged in the business of providing data security, archiving and privacy protections through its software-as-a-service
offerings, as well as any other activities that the Company undertakes while Employee is an Employee of the Company (together,
the “Business”); and

 

WHEREAS,
the Company desires to employ Employee as Chief Financial Officer (“CFO”), and Employee wishes to accept such
employment; and

 

WHEREAS,
the Board of Directors of the Company (the “Board”) has authorized the Company to enter into this Agreement.

 

WHEREAS,
Employee’s position will be a position of trust and responsibility with access to Confidential Information, Trade Secrets,
and information concerning executives and customers of the Company; and

 

WHEREAS,
the Trade Secrets and Confidential Information, and the relationship between the Company and each of its executives and customers
are valuable assets of the Company and may not be used for any purpose other than the Business; and

 

WHEREAS,
the Company and Employee have agreed upon the terms and conditions of Employee’s employment with the Company and the Parties
desire to express the terms and conditions in this Agreement.

 

NOW
THEREFORE, in consideration of the foregoing and the mutual promises and covenants contained herein and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the parties hereto agree that:

 

1.
Employment and Duties.

 

A.
The Company shall employ Employee as Chief Financial Officer of the Company, in accordance with the terms and conditions set forth
in this Agreement. Employee accepts employment on the terms set forth herein.

 

    	 

    	 	 	 

    

 

B.
Employee shall faithfully and to the best of his ability perform all duties of the Company related to his position with the Company,
including, but not limited to, all duties set forth in this Agreement and/or in the Bylaws of the Company related to the position
that he holds, as well as all duties that are reasonably assigned to him by the Board or its designees. Employee agrees to devote
his entire working time, attention, energy, and skills to the Company in furtherance of the Company’s best interests, while
so employed; provided that Employee may, to the extent not otherwise prohibited by this Agreement, (A) engage in such activities
as permitted in writing by the Company and (B) devote such amount of time as does not interfere or compete with the performance
of the Employee’s duties under this Agreement to any one or more of the following activities: (i) investing the Employee’s
personal assets in such manner as will not require services to be rendered by the Employee in the operation of the affairs of
the companies in which investments are made; or (ii) engaging in charitable and professional organization activities, including
serving on the Boards of Directors of charitable and professional organizations. Employee shall comply with all reasonable Company
policies, standards, rules, and regulations (the “Company Policies”) and all applicable government laws, rules, and
regulations that are now or hereafter in effect. Employee acknowledges receipt of copies of all written Company Policies that
are in effect as of the date of this Agreement.

 

2.
Term of Employment. Unless earlier terminated as provided herein, the initial term of this Agreement shall commence on
the Effective Date and shall continue until the one-year anniversary of the Effective Date (the “Initial Term”). After
the Initial Term, this Agreement shall automatically renew for successive additional one-year terms on the same terms and conditions
set forth herein, unless: (i) earlier terminated or amended as provided herein or (ii) either party gives written notice of non-renewal
at least thirty (30) days prior to the end of the Initial Term or any renewal term of this Agreement. The Initial Term of this
Agreement and all applicable renewals thereof are collectively referred to herein as the “Term.”

 

3.
Compensation and Benefits. During the Term, Employee shall receive compensation and benefits for the services performed
for the Company under this Agreement as follows:

 

(a)
Base salary.

 

	 	a.	Initial
    Base Salary. Employee shall receive a base salary of One Hundred Twenty Thousand and 00/100 Dollars ($120,000), payable
    in regular and equal installments in accordance with the Company’s regular payroll schedule and practices (“Base
    Salary”).
	 	 	 
	 	b.	Base
    Salary Modification 1. Employee shall receive a base salary of One Hundred Eighty Thousand and 00/100 Dollars ($180,000),
    payable in regular and equal installments in accordance with the Company’s regular payroll schedule and practices, upon
    the SEC declaring effective an S-1 to register shares of the Company’s common stock.
	 	 	 
	 	c.	Base
    Salary Modification 2. Employee shall receive a base salary of Two Hundred Twenty Thousand and 00/100 Dollars ($220,000),
    payable in regular and equal installments in accordance with the Company’s regular payroll schedule and practices, upon
    the Company achieving an annualized revenue run rate of at least Five Million and 00/100 Dollars ($5,000,000) measured at
    the time of an acquisition closing, and/or entering into new customer contracts; or trailing twelve (12) month gross booked
    revenues of Two Million Five Hundred Thousand and 00/100 Dollars ($2,500,000). 

 

    	 

    	 

    

 

(b)
Employee Benefits. Employee shall be entitled to receive those benefits that are made available to the other similarly-situated
executive employees of the Company, including, but not limited to, life, medical, and disability insurance, as well as retirement
benefits (collectively, the “Employee Benefits”), in accordance with the terms and conditions of the applicable plan
documents, provided that Employee meets the eligibility requirements thereof. The Company reserves the right to reduce, eliminate,
or change such Employee Benefits, in its sole discretion, subject to any applicable legal and regulatory requirements.

 

(c)
Equity Compensation Awards. The Board has approved an incentive stock option (“ISO”) granting Employee the
right to purchase up to 26,315,789 shares of the Company’s common stock under the Company’s Stock Incentive Plan (to
be determined and filed via S-8), at an option exercise price of $0.0019, equal to the weighted-average closing price of the common
stock for the previous five (5) trading days as of April 15, 2019, contingent upon Employee’s execution of this Agreement;
provided that such option shall be granted as a non-ISO to the extent it does not qualify for ISO treatment on the Effective Date.
This ISO award shall vest immediately upon the filing of the Company’s Form 10-Q for the period ending March 31, 2019. The
ISO award shall be contingent upon Employee’s execution of a standard Employee Incentive Option Agreement in substantially
the form attached as Exhibit A to this Agreement and the ISO award shall in all respects be subject to and governed by
the provisions of the Company’s Stock Incentive Plan and the Employee Incentive Option Agreement. The Board has also approved
a restricted stock award (“RSA”) of 23,684,211 shares of the Company’s common stock under the Company’s
Stock Incentive Plan, valued at $0.0019, equal to the weighted-average closing price of the common stock for the previous five
(5) trading days as of April 15, 2019, contingent upon the Employee’s executive of this Agreement. This RSA grant will vest
immediately upon the filing of the Company’s Form 10-Q for the period ending March 31, 2019. Employee shall also receive
an RSA grant every three months beginning at the time of the Agreement valued at Forty-Five Thousand and 00/100 Dollars ($45,000)
in shares equal to the grant value divided by the weighted-average closing price of the common stock for the previous five (5)
trading days. These quarterly grants will vest 100% twelve (12) months from date of grant.

 

(d)
Reimbursement of Expenses. The Company shall reimburse Employee for all reasonable out-of-pocket expenses incurred by Employee
that specifically and directly relate to the performance by Employee of the services under this Agreement, provided that Employee
complies with the Company Policies for reimbursement that are now or hereafter in effect. Each such expense shall be submitted
for reimbursement after they are incurred.

 

(e)
Paid Time Off. On a calendar year basis, Employee will: (i) earn paid time off (“PTO”) in accordance with the
Company’s PTO policy. In accordance with the Company Policies, all PTO that is earned by Employee shall be used or carried
over to the extent permitted and all paid personal leave that is received by Employee shall be used or forfeited. However, no
new PTO will be granted or accrued after one year hereunder until Employee uses all earned PTO. Upon the termination of the Employee’s
employment by the Company, all earned and unused PTO shall be paid in accordance with the terms of the Company Policies.

 

    	 

    	 	 	 

    

 

(f)
Bonus. Employee shall be eligible to receive a semi-annual bonus (the “Semi-annual Bonus”) tied to the success
of the Company’s annual business plan. The total of the Semi-annual Bonus payments will be targeted at 50% of the base salary
for the semi-annual period. All Semi-annual Bonus payments will be subject to the terms, conditions, and eligibility requirements
of the applicable bonus plan as it may exist from time to time, which may provide that the Semi-annual Bonus is payable in the
sole and absolute discretion of the Company. The Semi-annual Bonus shall be provided in a manner such that entitlement to and
payment of the Semi-annual Bonus is exempt from or compliant with Internal Revenue Code Section 409A.

 

4.
Withholding. The Company shall withhold from any payments or benefits under this Agreement, including, but not limited
to, any payments under Paragraphs 4(a), (c), (d), (e), and (f) of this Agreement, all federal, state, or local taxes or other
amounts, as may be required pursuant to applicable law, government regulation, or ruling.

 

5.
Termination. This Agreement and Employee’s employment by the Company shall or may be terminated as follows:

 

(a)
Expiration of the Term. This Agreement and Employee’s employment by the Company shall terminate upon the expiration
of the Term, if either party gives written notice of non-renewal at least thirty (30) days prior to the end of the Term.

 

(b)
Death of Employee. This Agreement and Employee’s employment by the Company shall terminate upon the death of Employee
(“Death”).

 

(c)
Discontinuance. The Company, immediately and without notice, may terminate this Agreement and Employee’s employment
by the Company upon the liquidation, dissolution, or discontinuance of business by the Company in any manner or the filing of
any petition by or against the Company under any federal or state bankruptcy or insolvency laws, provided that such petition is
not dismissed within sixty (60) days after filing (“Discontinuance”).

 

(d)
Termination by the Company for Just Cause. The Company, immediately and without notice, may terminate this Agreement and
Employee’s employment by the Company at any time for Just Cause. Termination for “Just Cause” shall include
termination for Employee’s: dishonesty; gross incompetence; willful misconduct; breach of fiduciary duty owed to the Company,
including any failure to disclose a material conflict of interest; failure to perform his duties as required by this Agreement
or to achieve the reasonable objectives mutually agreed upon by Employee and the Board or its designees; material violation of
any law (other than traffic violations or similar offenses); material failure to comply with Company Policies, including policies
prohibiting harassment, discrimination, and retaliation, or any other reasonable directives of the Board or its designees; conviction
of a felony of any nature or of a misdemeanor involving moral turpitude; use of illegal drugs or other illegal substance, or use
of alcohol in a manner that materially interferes with the performance of Employee’s duties under this Agreement; adverse
action or omission, without the consent or approval of the Company or not in accordance with performing Employee’s duties
hereunder, that would be required to be disclosed pursuant to public securities laws, even though such laws may not then apply
to the Company, that would limit the ability of the Company or any affiliated entity to sell securities under any federal or state
law, or that would disqualify the Company or any affiliated entity from any exemption otherwise available to it; disability; or
material breach of any provision of this Agreement, including provisions concerning confidentiality, proprietary information,
and restrictive covenants. For purposes of this subsection, the term “disability” means the inability of Employee,
because of the condition of his physical, mental, or emotional health, to satisfactorily perform the duties of his employment
hereunder, with or without a reasonable accommodation, for a continuous three-month period.

 

    	 

    	 	 	 

    

 

(e)
Termination by the Company Without Cause. The Company may terminate this Agreement and Employee’s employment by the
Company other than for “Just Cause,” as described in Paragraph 6(d) above, and other than upon “Discontinuance,”
as described in Paragraph 6(c) above, at any time for any reason by providing written notice to Employee, which termination shall
be effective immediately (“Without Cause”). For the avoidance of doubt, a notice by the Company that the Term of this
Agreement shall not be automatically renewed as provided in Paragraph 2 of this Agreement shall constitute a termination by the
Company Without Cause.

 

(f)
Termination by Employee for Good Reason. Employee may terminate this Agreement and his employment by the Company for “Good
Reason” (as defined herein), provided that: (i) Employee provides the Company with written notice of the Good Reason within
ninety (90) days of the initial actions or inactions of the Company giving rise to Good Reason; (ii) the Company does not cure
such conditions within sixty (60) days of such notice (the “Cure Period”); (iii) Employee terminates his employment
under this Agreement within thirty (30) days of the expiration of the Cure Period; and (iv) the Company has not, prior to Employee
giving notice of Good Reason, provided Employee with notice of termination or of non-renewal under this Agreement.

 

“Good
Reason” shall mean the occurrence of any of the following events within six (6) months following a Change of Control (as
defined herein) and without Employee’s consent: (i) a material diminishment in Employee’s responsibilities from those
he had immediately prior to the Change of Control; (ii) a material reduction in Employee’s base salary; (iii) Employee’s
place of employment is relocated more than fifty (50) miles from the location where Employee worked immediately prior to the Change
of Control; or (iv) a material breach of this Agreement by the Company.

 

    	 

    	 	 	 

    

 

A
“Change of Control” shall be deemed to have occurred if: (i) any person or group of persons (as defined in Section
13(d) and 14(d) of the Securities Exchange Act of 1934) together with its affiliates, excluding employee benefit plans of the
Company, becomes, directly or indirectly, the “beneficial owner” (as defined in Rule 13d-3 promulgated under the Securities
Exchange Act of 1934) of securities or ownership interests of the Company, representing 51% or more of the combined voting power
of the Company’s then outstanding securities or ownership interests; or (ii) during the then existing term of the Agreement,
as a result of a tender offer or exchange offer for the purchase of securities or ownership interests of the Company (other than
such an offer by the Company for its own securities), or as a result of a proxy contest, merger, consolidation or sale of assets,
or as a result of any combination of the foregoing, individuals who at the beginning of any year period during such term constitute
the Company Board, plus new directors whose election by the Company’s shareholders is approved by a vote of at least two-thirds
of the outstanding voting shares of the Company, cease for any reason during such year period to constitute at least two-thirds
of the members of such Board; or (iii) the shareholders of the Company approve a merger or consolidation of the Company with any
other corporation or entity regardless of which entity is the survivor, other than a merger or consolidation which would result
in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding
or being converted into voting securities of the surviving entity) at least 60% of the combined voting power of the voting securities
of the Company or such surviving entity outstanding immediately after such merger or consolidation which entity continues to be
the sole or majority owner of the Company; or (iv) any event which the Company’s Board of Directors determines should constitute
a Change of Control. Notwithstanding anything in this Agreement to the contrary, in no event shall any of the following occurrences
constitute a “Change of Control”: (i) the Company’s making any assignment for the benefit of its creditors or
consenting to the appointment of a receiver or commencing any proceeding in bankruptcy or for dissolution, liquidation, winding-up,
composition or other relief under state or federal bankruptcy laws or (ii) any proceeding in bankruptcy or for dissolution, liquidation,
winding-up, composition or other relief under state or federal bankruptcy laws being commenced against the Company, or a receiver
or trustee being appointed for the Company or a substantial part of its property.

 

(g)
Termination by Employee Without Good Reason. Employee may terminate this Agreement and his employment by the Company for
reasons other than Good Reason thirty (30) days after written notice of Employee’s resignation is received by the Company
(“Resignation”).

 

(h)
Obligations of the Company Upon Termination.

 

i.
Upon the termination of this Agreement: (A) pursuant to the expiration of the Term, under Paragraph 6(a) of this Agreement, following
Employee’s notice of non-renewal pursuant to Paragraph 2 of this Agreement; (B) pursuant to Paragraph 6(b) of this Agreement
(“Death”); (C) by the Company pursuant to Paragraph 6(c) of this Agreement (“Discontinuance”) or Paragraph
6(d) of this Agreement (“Just Cause”); (D) by Employee pursuant to Paragraph 6(g) of this Agreement (“Resignation”);
or (E) for any reason other than those set forth in Paragraph 6(h)(ii); the Company shall have no further obligation hereunder
other than the payment of all compensation and other benefits payable to Employee through the date of such termination.

 

ii.
Upon the termination of this Agreement (and subject to Employee’s execution of a release under Paragraph 6 of this Agreement
and compliance with his obligations under Paragraphs 8, 9, 10, and 11 of this Agreement): (A) by Employee pursuant to Paragraph
6(f) of this Agreement (“Good Reason”); (B) by the Company pursuant to Paragraph 6(e) of this Agreement (“Without
Cause”) within six (6) months following a Change of Control; or (C) pursuant to the expiration of the Term, under Paragraph
5(a) of this Agreement, following the Company’s notice of non-renewal pursuant to Paragraph 2 of this Agreement within six
(6) months following a Change of Control; the Company shall pay Employee an amount equal to six (6) months of his then current
base salary (less all applicable deductions), payable over six consecutive months in equal installment payments paid in accordance
with the Company’s regular payroll schedule, beginning on the first regular payroll date occurring on or after the date
on which the release of claims required by Paragraph 6 of this Agreement becomes effective and non-revocable.

 

    	 

    	 	 	 

    

 

iii.
Upon the termination of this Agreement (and subject to Employee’s execution of a release under Paragraph 6 of this Agreement
and compliance with his obligations under Paragraphs 8, 9, 10, and 11 of this Agreement): (A) by the Company pursuant to Paragraph
6(e) of this Agreement (“Without Cause”) not occurring within six months following a Change of Control; or (B) pursuant
to the expiration of the Term, under Paragraph 5(a) of this Agreement, following the Company’s notice of non-renewal pursuant
to Paragraph 2 of this Agreement and not within six months following a Change of Control; the Company shall pay Employee an amount
equal to six (6) months of his then current base salary (less all applicable deductions), payable over six consecutive months
in equal installment payments paid in accordance with the Company’s regular payroll schedule, beginning on the first regular
payroll date occurring on or after the date on which the release of claims required by Paragraph 7 of this Agreement becomes effective
and non-revocable.

 

iv.
Notwithstanding the terms of the Company’s equity compensation plans and applicable award agreements, upon the occurrence
of a Change of Control or a termination of this Agreement by the Company pursuant to Paragraph 6(e) of this Agreement (“Without
Cause”) not occurring within six months following a Change of Control (and subject to Employee’s execution of a release
under Paragraph 7 of this Agreement and compliance with his obligations under Paragraphs 8, 9, 10, and 11 of this Agreement):
(A) all of Employee’s outstanding unvested time-based equity awards shall become fully vested and any restrictions thereon
shall lapse and (B) all of Employee’s outstanding unvested performance-based equity awards shall be deemed achieved at target
levels with respect to performance goals or other vesting criteria.

 

v.
Notwithstanding any provision in this Agreement to the contrary, any payment conditioned upon the release required by Paragraph
7 shall be made, or commence, as applicable, within ninety (90) days of the termination of Employee’s employment. To the
extent that any payment due under this Paragraph 6 is not exempt from Section 409A, such amount shall be paid in a lump sum no
later than seventy-four (74) days following the Employee’s termination of employment.

 

6.
Release of Claims. Notwithstanding any provision of this Agreement to the contrary, the Company’s obligation to provide
any severance payment under Paragraph 5(h)(ii) or (iii) of this Agreement is conditioned upon Employee’s execution of an
enforceable release of any and all claims arising before the date that he signs the release, in a form which is reasonable and
which is satisfactory to the Company (satisfaction of the Company is not to be unreasonably withheld), and his compliance with
the provisions of Paragraphs 8, 9, 10, and 11 of this Agreement. If Employee fails to execute such a release or fails to comply
with such terms of this Agreement, then the Company’s obligation to make any payments to him ceases on the effective termination
date. The release of claims shall be provided to Employee within seven (7) days of the termination of his employment, and Employee
must execute it within the time period specified in the release (which shall not be longer than forty-five (45) days from the
date upon which he receives it). Such release shall not be effective until any applicable revocation period has expired.

 

    	 

    	 	 	 

    

 

7.
Definitions. For purposes of this Agreement, the following terms shall have the following meanings:

 

(a)
“Confidential Information” shall mean: (i) any and all non-public or otherwise confidential proprietary knowledge,
material, or information of the Company, including any and all knowledge, material, or information that is designated as Confidential
Information by the Company and any and all confidential knowledge, material, or information that becomes generally known to the
public as a result of a disclosure by Employee, or any other person or entity who is obligated to treat such knowledge, material,
or information confidentially, and (ii) any and all non-public or otherwise confidential proprietary knowledge, material, or information
of others who disclose that knowledge, material, or information to the Company, including any and all knowledge, material, or
information designated as Confidential Information by the Company, or those others and any and all confidential knowledge, material,
or information that becomes generally known to the public as a result of a disclosure by Employee, or any other person or entity
who is obligation to treat such knowledge, material, or information confidentially. Confidential Information includes, but is
not limited to, the following types of knowledge, material, or information (whether or not reduced to writing): trade secrets;
concepts; designs; discoveries; ideas; know-how; processes; techniques; Inventions (as defined herein); drawings; specifications;
models; data; software in various stages of development; source and object code; documentation; diagrams; flow charts; research;
procedures; marketing devices, processes, computer programs and related source code and object code, mask works, and methods,
together with any improvements thereon or thereto, and development techniques, materials, plans, and information; business methods,
procedures, and policies; current and prospective customers names and lists and other information related to current and prospective
customers; prices, including price lists, policies, and formulas; profit margins, data, and formulas; financial information; a
mask work and whether or not reduced to practice, including, but derivative works made therefrom, and know-how, descriptions,
sketches, drawings, or other knowledge, manuals and methodologies; and employee files and information.

 

(b)
“Inventions” shall mean ideas, concepts, techniques, inventions, discoveries, and works of authorship, whether or
not patentable or protectable by copyright or as information, or material related thereto.

 

(c)
“Intellectual Property Rights” shall mean all patent, trademark, and copyright rights, moral rights, rights of attribution
or integrity, trade secret rights, or other proprietary or intellectual property rights.

 

(d)
“Competing Business” shall mean any corporation, partnership, person, or other entity that is primarily engaged in
researching, developing manufacturing, marketing, distributing, or selling any product, service, or technology that is competitive
with any part of the Company’s business. For the avoidance of doubt, any with less than 20% of its total revenue derived
from these activities, is not a Competing Business.

 

    	 

    	 	 	 

    

 

(e)
“Company’s Business” shall mean the development, marketing, distribution, or sale of, including research directed
to, any product, service, or technology data security industry. As of the date of this Agreement, Company’s Business includes,
but is not limited to: (i) marketing and distributing data security and privacy applications, and (ii) developing and acquiring
data security and privacy software companies. Employee understands that during Employee’s employment with the Company, the
Company’s Business may expand or change, and Employee agrees that any such expansions or changes shall expand or contract
the definition of the Company’s Business and Employee’s obligations under this Agreement accordingly.

 

(f)
“Territory” shall mean the following severable geographic areas: (i) within a 100 mile radius of any location where
the Employee performed services for the Company for the two (2) years preceding Employee’s termination; and (ii) within
50 miles of any county where the Company sells or markets its products or services.

 

8.
Covenant Not to Compete. As a result of Employee’s employment by the Company: (i) Employee will have access to trade
secrets and Confidential Information of the Company, including, but not limited to, valuable information about its intellectual
property, business operations and methods, and the persons with which it does business in various locations throughout the world,
that is not generally known to or readily ascertainable by a Competing Business, (ii) Employee will develop relationships with
the Company’s customers and others with which the Company does business, and these relationships are among the Company’s
most important assets, (iii) Employee will receive specialized knowledge of and specialized training in the Company’s Business,
and (iv) Employee will gain such knowledge of the Company’s Business that, during the course of Employee’s employment
with the Company and for a period of one year following the termination thereof, Employee could not perform services for a Competing
Business without inevitably disclosing the Company’s trade secrets and Confidential Information to that Competing Business.
Accordingly, Employee agrees to the following:

 

(a)
While employed by the Company, Employee will not, without the express written consent of an authorized representative of the Company:
(i) perform services (as an employee, independent contractor, officer, director, or otherwise) within the Territory for any Competing
Business, (ii) engage in any activities (or assist others to engage in any activities) within the Territory that compete with
the Company’s Business, (iii) own or beneficially own an equity interest in a Competing Business, (iv) request, induce,
or solicit (or assist others to request, induce, or solicit) any customers, prospective customers, or suppliers of the Company
to curtail or cancel their business with the Company, or to do business within the scope of the Company’s Business with
a Competing Business, (v) request, induce, or solicit (or assist others to request, induce, or solicit) for the benefit of any
Competing Business any employee or independent contractor of the Company to terminate his or her employment or independent contractor
relationship with the Company, or (vi) employ (or assist others to employ) for the benefit of any Competing Business any person
who has been employed by the Company within the last year of Employee’s employment with the Company.

 

    	 

    	 	 	 

    

 

(b)
For a period of one year following the termination of Employee’s employment with the Company, Employee will not, without
the express written consent of an authorized representative of the Company: (i) perform services (as an employee, independent
contractor, officer, director, or otherwise), within the Territory for any Competing Business, that are the same or similar to
any services that Employee performed for the Company or that otherwise utilize skills, knowledge, and/or business contacts and
relationships that Employee utilized while providing services to the Company, (ii) engage in any activities (or assist others
to engage in any activities) within the Territory that compete with the Company’s Business, (iii) own or beneficially own
an equity interest in a Competing Business, (iv) request, induce, or solicit (or assist others to request, induce, or solicit)
any customers, prospective customers, or suppliers of the Company, which were customers, prospective customers, or suppliers of
the Company during the last year of Employee’s employment with the Company, to curtail or cancel their business with the
Company, or to do business within the scope of the Company’s Business with a Competing Business, (v) request, induce, or
solicit (or assist others to request, induce, or solicit) any customers, prospective customers, or suppliers of the Company with
which Employee worked or had business contact during the last year of Employee’s employment with the Company to curtail
or cancel their business with the Company, or to do business within the scope of the Company’s Business with a Competing
Business, (vi) request, induce, or solicit (or assist others to request, induce, or solicit) any employee or independent contractor
of the Company to terminate his or her employment or independent relationship with the Company, (vii) request, induce, or solicit
(or assist others to request, induce, or solicit) any person who has been employed by the Company within the last year of Employee’s
employment by the Company or thereafter to be employed with a Competing Business, or (viii) employ or engage as a contractor (or
assist others to employ or engage as a contractor) any person who has been employed by the Company within the last year of Employee’s
employment by the Company or thereafter. These obligations will continue for the specified period regardless of whether the termination
of Employee’s employment was voluntary or involuntary or with or without cause, and the specified period shall be tolled
and shall not run during any time in which Employee fails to abide by these obligations.

 

(c)
As an exception to the above restrictions, Employee may own passive investments in Competing Businesses, (including, but not limited
to, indirect investments through mutual funds), provided that the securities of the Competing Business are publicly traded and
Employee does not own or control more than two percent of the outstanding voting rights or equity of the Competing Business.

 

9.
Confidentiality.

 

(a)
All documents or other records, paper or electronic, that, in any way, constitute, contain, incorporate, or reflect any Confidential
Information and all proprietary rights therein, including Intellectual Property Rights, shall belong exclusively to the Company,
and Employee agrees to promptly deliver to the Company, upon request or upon termination of Employee’s employment with the
Company, all copies of such materials and Confidential Information in Employee’s possession, custody, or control, as well
as all other property of the Company in Employee’s possession, custody, or control. Likewise, Employee agrees to promptly
deliver to the Company, upon request or upon termination of Employee’s employment with the Company, all copies of all documents
or other records that, in any way, constitute, contain, incorporate, or reflect any Confidential Information of others that was
disclosed or provided to Employee during the Term that is in Employee’s possession, custody, or control.

 

    	 

    	 	 	 

    

 

(b)
Employee agrees, during the Term and thereafter: (i) to hold in confidence and treat with strict confidentiality all Confidential
Information, (ii) not to directly or indirectly reveal, report, publish, disclose, or transfer any Confidential Information to
any person or entity, and (iii) not to utilize any Confidential Information for any purpose, other than in the course and scope
of Employees work for the Company. If Employee is required to disclose Confidential Information pursuant to a court order or subpoena
or such disclosure is necessary to comply with applicable law, the undersigned shall: (i) promptly notify the Company before any
such disclosure is made and provide the Company with reasonable and ample time within which to object to or oppose any such disclosure,
(ii) at the Company’s request and expense take all reasonably necessary steps to defend against such disclosure, including
defending against the enforcement of the court order, subpoena, or other applicable law, and (iii) permit the Company to participate
with counsel of its choice in any related proceedings.

 

10.
Proprietary Information.

 

(a)
Employee agrees that any Inventions created, conceived, developed, or reduced to practice, in whole or in part, by Employee, either
solely or in conjunction with others, during or after the Term that arise in any way from the use of or reliance on any Confidential
Information or any of the Company’s equipment, facilities, supplies, trade secret information, or time, that relate to the
Company’s Business or the Company’s demonstrably anticipated business, research, or development, or that result from
any work performed by Employee for, on behalf of, or at the direction of the Company, shall belong exclusively to the Company
and shall be deemed part of the Confidential Information for purposes of this Agreement, whether or not fixed in a tangible medium
of expression. Employee agrees that all rights, title, and interest in and to all such Inventions, including, but not limited
to, Intellectual Property Rights shall vest and reside in, and shall be the exclusive property of, the Company. Without limiting
the foregoing, Employee agrees that any and all such Inventions shall be deemed to be “works made for hire” and that
the Company shall be deemed the sole and exclusive owner thereof. In the event and to the extent that any such Inventions are
determined not to constitute “works made for hire” or that, by operation of law or otherwise, any right, title, or
interest in or to the Inventions, including, but not limited to, any Intellectual Property Rights, vests not in the Company, but,
rather, in Employee, Employee hereby: (i) irrevocably and unconditionally assigns and transfers to the Company all rights, title,
and interest in and to any such Inventions, including, but not limited to, all Intellectual Property Rights and (ii) forever waives
and agrees never to assert all such rights, title, and interest.

 

(b)
Employee agrees to promptly and fully disclose in writing to the Board of Directors of the Company: (i) any Invention created,
conceived, developed or reduced to practice by Employee, either solely or in conjunction with others, during the Term and (ii)
any such Invention created, conceived, developed, or reduced to practice after the Term that belongs exclusively to the Company
pursuant to the provisions of Paragraph 11(a) of this Agreement. For the avoidance of doubt, in no event shall any provision of
this Agreement, including without limitation Paragraph 11(b), provide or be construed to provide Employee or any other party with
any license or other right or authority to create, conceive, develop, or reduce to practice, after the Term, any Invention in
which the Company has an ownership interest, without the prior written consent of the Company.

 

    	 

    	 	 	 

    

 

(c)
Employee agrees to assist the Company, at the Company’s expense, either during or subsequent to the Term, to obtain and
enforce for the Company’s own benefit, in any country, Intellectual Property Rights in connection with any and all Inventions
created, conceived, developed, or reduced to practice by Employee (in whole or in part) that belong or have been assigned to the
Company pursuant to the provisions of Paragraph 11(a) of this Agreement. Upon request, either during or subsequent to the Term,
Employee will execute all applications, assignments, instruments, and papers and perform all acts that the Company or its counsel
may reasonably deem necessary or desirable to obtain, maintain, or enforce any Intellectual Property Rights in connection with
any such Inventions or to otherwise protect the interests of the Company in those Inventions.

 

11.
Acknowledgements, Representations, and Warranties.

 

(a)
Employee acknowledges that the Company has a strict policy against using proprietary information belonging to any other person
or entity without the express permission of the owner of that information.

 

(b)
Employee represents and warrants to the Company that Employee’s performance under this Agreement and as an employee of the
Company does not and will not breach any non-competition, non-solicitation, or confidentiality agreement to which Employee is
a party. Employee represents and warrants to the Company that Employee has not entered into, and agrees not to enter into, any
agreement that conflicts with or violates this Agreement.

 

(c)
Employee represents and warrants to the Company that Employee has not brought and shall not bring to the Company, or use in the
performance of Employee’s responsibilities for the Company, any materials or documents of a former employer that are not
generally available to the public or that did not belong to Employee prior to Employee’s employment with the Company, unless
Employee has obtained written authorization from the former employer or other owner for their possession and use and provided
the Company with a copy thereof.

 

12.
Indemnification. The Employee will be eligible for indemnification to the fullest extent authorized under the Company’s
Articles of Incorporation and By-Laws (as applicable) and will be eligible for coverage under the Company’s Director’s
& Officer’s liability insurance policy as approved by the Board, subject to the terms and conditions contained therein,
if and when such a policy is obtained.

 

13.
Entire Agreement. This Agreement constitutes the entire agreement of the parties with respect to the matters set forth
herein and supersedes any prior agreements or understandings between them, whether written or oral.

14.
Attorneys’ Fees. In the event of litigation relating to this Agreement, the prevailing party shall be entitled to
recover attorney’s fees and costs of litigation in addition to all other remedies available at law or in equity.

 

15.
Waiver. The failure of either party to insist, in any one or more instance, upon performance of the terms and conditions
of this Agreement shall not be construed as a waiver or a relinquishment of any right granted hereunder or of the future performance
of any such term or condition.

 

    	 

    	 	 	 

    

 

16.
Notices. Any notice to be given under this Agreement shall be deemed sufficient if addressed in writing and delivered personally,
by telefax with receipt acknowledged, or by registered or certified U.S. mail to the following:

 

For
the Company:

Chairman
of the Board of Directors

LandStar,
Inc.

c/o
Data443 Risk Mitigation, Inc.

101
J Morris Commons Lane, Suite 105

Morrisville,
North Carolina 27560

Fax:
(919) 526-1070

 

For
Employee:

Steven
C. Dawson

 

17.
Severability. In the event that any provision of any paragraph of this Agreement shall be deemed to be invalid or unenforceable
for any reason whatsoever, it is agreed such invalidity or unenforceability shall not affect any other provision of such paragraph
or of this Agreement, and the remaining terms, covenants, restrictions or provisions in such paragraph and in this Agreement shall
remain in full force and effect and any court of competent jurisdiction may so modify the objectionable provision as to make it
valid, reasonable, and enforceable. In the event that a court determines that the length of time, the geographic area, or the
activities prohibited under this Agreement are too restrictive to be enforceable, the court may reduce the scope of the restriction
to the extent necessary to make the restriction enforceable.

 

18.
Amendment. This Agreement may be amended only by an agreement in writing signed by each of the parties hereto.

 

19.
Restrictive Covenants Are Reasonable. The market for the Company’s services and the Company’s Business is highly
specialized and highly competitive such that other companies and business entities compete with the Company in various locations
throughout the world. The provisions set forth in this Agreement: (i) are reasonably necessary to protect the Company’s
legitimate business interests, (ii) are reasonable as to the time, territory, and scope of activities that are restricted, (iii)
do not interfere with Employee’s ability to earn a comparable living or secure employment in the field of Employee’s
choice, (iv) do not interfere and are not inconsistent with public policy or the public interest, and (v) are described with sufficient
accuracy and definiteness to enable Employee to understand the scope of the restrictions on Employee.

 

20.
Injunctive Relief. Because of the unique nature of the Confidential Information, Employee understands and agrees that the
Company will suffer irreparable harm in the event that Employee fails to comply with any of Employee’s obligations under
Paragraphs 8, 9, 10, or 11 of this Agreement and that monetary damages will be inadequate to compensate the Company for such breach.
Accordingly, Employee agrees that the Company will, in addition to any other remedies available to it at law or in equity, be
entitled to injunctive relief to enforce the terms of Paragraphs 8, 9, 10, or 11 of this Agreement.

    	 

    	 	 	 

    

 

21.
Publication. Employee hereby authorizes the Company to provide a copy of this Agreement to any and all of Employee’s
future employers and to notify any and all such future employers that the Company intends to exercise its legal rights arising
out of or in connection with this Agreement and/or any breach or any inducement of a breach hereof.

 

22.
Survival. Employee agrees that: (i) Employee’s employment with the Company is contingent upon Employee’s execution
of this Agreement, which is a material inducement to the Company to offer employment and the compensation and benefits hereunder
to Employee and to provide Confidential Information to Employee, and (ii) Paragraphs 8, 9, 10, and 11 of this Agreement shall
survive any termination for any reason whatsoever of Employee’s employment with the Company.

 

23.
Governing Law. This Agreement shall be construed, interpreted, and governed in accordance with the laws of the state of
North Carolina, without regard to the conflicts of laws principles thereof. The state and federal courts in North Carolina shall
be the exclusive venues for the adjudication of all disputes arising out of this Agreement, and the parties consent to the exercise
of personal jurisdiction over them in any such adjudication and hereby waive any and all objections and defenses to the exercise
of such personal jurisdiction.

 

24.
Benefit. This Agreement shall be binding upon and inure to the benefit of and shall be enforceable by and against the Company,
its successors and assigns, and Employee, his heirs, beneficiaries, and legal representatives. The Company may assign this Agreement
or any rights hereunder, or delegate any obligations hereunder, without the consent of Employee. Employee shall not assign this
Agreement or delegate Employee’s obligations hereunder. Employee’s right to receive payments under this Agreement
shall not be subject to alienation, anticipation, commutation, sale, assignment, encumbrance, setoff, charge, pledge, offset or
hypothecation or to execution, levy, attachment, or similar process or assignment by operation of law, and any attempt, voluntary
or involuntary, to effect any such action shall be null, void and of no effect.

 

    	 

    	 	 	 

    

 

25.
Compliance with Section 409A.

 

(a)
Parties’ Intent. The parties intend that the payments and benefits to which Employee may become entitled in connection
with Employee’s employment under this Agreement will be exempt from or comply with Section 409A of the Code and the regulations
and other guidance promulgated thereunder (collectively, “Section 409A”) and all provisions of this Agreement shall
be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. All severance payments
hereunder are intended to qualify as short-term deferrals meeting the requirements of Treasury Regulation Section 1.409A-1(b)(4)
or as involuntary severance payments satisfying the requirements of Treasury Regulation Section 1.409A-1(b)(9)(iii) and this Agreement
shall be construed in accordance with such intent. If any provision of this Agreement (or of any award of compensation, including
equity compensation or benefits) would cause Employee to incur any additional tax or interest under Section 409A, the Company
shall, upon the specific request of Employee, use its reasonable business efforts to in good faith reform such provision to comply
with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Employee
and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes
that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable
business efforts to amend any plan or program in which Employee participates to bring it in compliance with Section 409A.

 

(b)
Separation from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision
of this Agreement relating to the payment of any amounts or benefits upon or following a termination of employment unless such
termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any
such provision of this Agreement, references to a “termination,” “termination of employment,” “separation
from service” or like terms shall mean Separation from Service.

 

(c)
Separate Payments. Each installment payment required under this Agreement shall be considered a separate payment for purposes
of Section 409A.

 

(d)
Delayed Distribution to Key Employees. If the Company determines in accordance with Sections 409A and 416(i) of the Internal
Revenue Code of 1986, as amended, and the regulations promulgated thereunder, in the Company’s sole discretion, that Employee
is a Key Employee of the Company on the date Employee’s employment with the Company terminates and that a delay in benefits
provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation
of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be
delayed for a period of six (6) months following the date of termination of Employee’s employment (the “409A Delay
Period”). In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement
that would otherwise be due and payable to Employee during the 409A Delay Period shall be paid to Employee in a lump sum cash
amount in the month following the end of the 409A Delay Period. For purposes of this Agreement, “Key Employee” shall
mean an employee who, on an Identification Date (“Identification Date” shall mean each December 31) is a key employee
as defined in Section 416(i) of the Code without regard to paragraph (5) thereof. If Employee is identified as a Key Employee
on an Identification Date, then Employee shall be considered a Key Employee for purposes of this Agreement during the period beginning
on the first April 1 following the Identification Date and ending on the following March 31.

 

a.
Reimbursement. To the extent that any right to reimbursement of expenses or payment of any benefit in-kind under this Agreement
constitutes nonqualified deferred compensation (within the meaning of Section 409A), (i) any such expense reimbursement shall
be made by the Company no later than the last day of the taxable year following the taxable year in which such expense was incurred
by the Employee, (ii) the right to reimbursement on in-kind benefits shall not be subject to liquidation or exchange for another
benefit, and (iii) the amount of expenses eligible for reimbursement or in-kind benefits provided during any taxable year shall
not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable year.

    	 

    	 	 	 

    

 

26.
Confidentiality. The terms and conditions of this Agreement are highly confidential. Accordingly, Employee acknowledges
and agrees that neither Employee nor anyone acting on Employee’s behalf has made or will make any disclosures concerning
the terms of this Agreement to any person or entity, except: (i) Employee’s spouse or domestic partner; (ii) Employee’s
attorneys, accountants, or financial advisors, but only to the extent disclosure is necessary to obtain legal or professional
services from such persons; or (iii) a government agency or court of competent jurisdiction pursuant to a legally enforceable
subpoena. If Employee makes any disclosure to any person described in sub-clauses (i) or (ii) above, Employee shall inform such
person of this confidentiality provision and shall receive the individual’s agreement not to make any use, disclosure, or
announcement concerning this Agreement in violation of this Section. However, nothing shall prevent the Company from disclosing
any or all provisions of this Agreement in accordance with applicable securities rules.

 

27.
Affirmation. EMPLOYEE acknowledgeS
that employee HAS carefully read this Agreement, EMPLOYEE knowS and understandS its terms and conditions, and employee HAS had
the opportunity to ask the Company any questions employee may have had prior to signing this Agreement.

 

    	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

 

	 	LandStar,
    Inc.
	 	 	 
	 	By:	

                                                                                 

	 	 	Jason
    Remillard
	 	 	Chairman
    and President
	 	 	 
	 	EMPLOYEE
	 	 	 
	 	By:	

                                                                                 

	 	 	Steven
    C. DawsonExhibit
4.4

 

WARRANT
AGREEMENT

 

THIS
WARRANT AGREEMENT (the “Agreement”), dated as of May 9, 2019, is between Health Sciences Acquisitions Corporation,
a Delaware corporation, (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation
(the “Warrant Agent”).

 

WHEREAS,
the Company has received a binding commitment from Health Sciences Holdings, LLC, a Delaware limited liability company (the “Sponsor”),
to purchase 10,000,000 warrants (or up to 11,500,000 warrants if the underwriters in the Public Offering (defined below) exercise
their over-allotment option in full), bearing the legend set forth in Exhibit B hereto (the “Private Placement Warrants”),
pursuant to a Private Placement Warrants Purchase Agreement (the “Private Placement Warrants Purchase Agreement”);
and

 

WHEREAS,
the Company may issue up to an additional 2,300,000 Warrants, which will be identical to the Private Placement Warrants, in consideration
of certain working capital loans that may be made by the Sponsor or the Company’s officers, directors or affiliates; and

 

WHEREAS,
the Company is engaged in an initial public offering (the “Public Offering”) of units, each unit comprised of one
share of Common Stock (as defined below) and one Public Warrant (as defined below) (the “Units”) and, in connection
therewith, has determined to issue and deliver up to 11,500,000 Warrants (the “Public Warrants” and, together with
the Private Placement Warrants, the “Warrants”) to the public investors, each such whole Warrant evidencing the right
of the holder thereof to purchase one-half of one share of Common Stock of the Company, par value $0.0001 per share (“Common
Stock”), for $11.50 per whole share, subject to adjustment as described herein; and

 

WHEREAS,
the Company has filed with the Securities and Exchange Commission (the “Commission”) a Registration Statement on Form
S-1 (No. 333-230893) (the “Registration Statement”) and prospectus (the “Prospectus”) for the registration,
under the Securities Act of 1933, as amended (the “Act”), of, among other securities, the Warrants; and

 

WHEREAS,
the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection
with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants; and

 

WHEREAS,
the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants;
and

 

WHEREAS,
all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company
and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company,
and to authorize the execution and delivery of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1.             Appointment
of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the
Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth
in this Agreement.

 

2.             Warrants.

 

2.1           Form
of Warrant. Each Warrant shall be issued in registered form only, shall be in substantially the form of Exhibit A hereto,
the provisions of which are incorporated herein and shall be signed by, or bear the facsimile signature of, the Chairman of the
Board of Directors or Chief Executive Officer and Treasurer, Secretary or Assistant Secretary of the Company and shall bear a
facsimile of the Company’s seal. In the event the person whose facsimile signature has been placed upon any Warrant shall
have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with
the same effect as if he or she had not ceased to be such at the date of issuance.

 

     

     

    

 

2.2          Uncertificated
Warrants. Notwithstanding anything herein to the contrary, any Warrant, or portion thereof, may be issued as part of, and
be represented by, a Unit, and any Warrant may be issued in uncertificated or book-entry form through the Warrant Agent and/or
the facilities of The Depository Trust Company (the “Depositary”) or other book-entry depositary system, in each case
as determined by the Board of Directors of the Company or by an authorized committee thereof. Any Warrant so issued shall have
the same terms, force and effect as a certificated Warrant that has been duly countersigned by the Warrant Agent in accordance
with the terms of this Agreement.

 

2.3          Effect
of Countersignature. Except with respect to uncertificated Warrants as described above, unless and until countersigned by
the Warrant Agent pursuant to this Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder
thereof.

 

2.4          Registration.

 

2.4.1       Warrant
Register. The Warrant Agent shall maintain books (“Warrant Register”) for the registration of original issuance
and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and
register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions
delivered to the Warrant Agent by the Company.

 

2.4.2       Registered
Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant shall be registered upon the Warrant Register (a “Registered Holder”)
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other
writing on the Warrant certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise
thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

2.5          Detachability
of Warrants. The securities comprising the Units will not be separately transferable until the 90th day following the date
of the Prospectus or, if such 90th day is not on a day, other than a Saturday, Sunday or federal holiday, on which banks in New
York City are generally open for normal business (a “Business Day”), then on the immediately succeeding Business Day
following such date, or earlier with the consent of Chardan Capital Markets LLC (the “Underwriter”), but in no event
will the Underwriter allow separate trading of the securities comprising the Units until (A) the Company has filed a Current Report
on Form 8-K with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds
of the Public Offering, including the proceeds received by the Company from the exercise of the underwriters’ over-allotment
option in the Public Offering, and (B) the Company issues a press release and files with the Commission a Current Report on Form
8-K announcing when such separate trading shall begin. After the consummation of an initial Business Combination, all Warrants
will automatically begin separate trading.

 

2.6          Private
Placement Warrant Attributes. The Private Placement Warrants will be issued in the same form as the Public Warrants but they
(i) will not be redeemable by the Company and (ii) may be exercised for cash or on a cashless basis at the holder’s option,
in either case as long as the Private Placement Warrants are held by the initial purchasers or their affiliates and permitted
transferees (as prescribed in Section 5.6 hereof). Once a Private Placement Warrant is transferred to a holder other than an affiliate
or permitted transferee, it shall be treated as a Public Warrant hereunder for all purposes.

 

3.           Terms
and Exercise of Warrants

 

3.1           Warrant
Price. Each full Warrant shall, when countersigned by the Warrant Agent, entitle the Registered Holder thereof, subject to
the provisions of such Warrant and of this Warrant Agreement, to purchase from the Company the number shares of Common Stock stated
therein, at the price of $11.50 per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of
this Section 3.1. The term “Warrant Price” as used in this Warrant Agreement refers to the price per share at which
the shares of Common Stock may be purchased at the time a Warrant is exercised. The Company will not issue fractional shares.
As a result, such Registered Holder must exercise Warrants in multiples of two at the Warrant Price (subject to adjustment) in
order to validly exercise his, her or its Warrants.

 

     2

     

    

 

3.2          Duration
of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”) commencing on the later
of (i) 30 days after the consummation by the Company of its initial merger, share exchange, asset acquisition, share purchase,
reorganization or other similar business combination with one or more businesses or entities (the “Business Combination”)
(as described more fully in the Registration Statement) or (ii) 12 months from the closing of the Public Offering, and terminating
at 5:00 p.m., New York City time on the earlier to occur of (a) five years from the consummation of the Business Combination and
(ii) the Redemption Date as provided in Section 6.2 hereof (in each case, the “Expiration Date”). Except with respect
to the right to receive the Redemption Price (as set forth in Section 6 hereunder), each Warrant not exercised on or before the
Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease
at the close of business on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by
delaying the Expiration Date; provided, however, that the Company will provide at least twenty (20) days’ prior written
notice of any such extension to registered holders of the Warrants and, provided further that any such extension shall be identical
in duration among all the Warrants.

 

3.3          Exercise
of Warrants.

 

3.3.1        Payment.
Subject to the provisions of the Warrant and this Warrant Agreement, a Warrant, when countersigned by the Warrant Agent, may be
exercised by the Registered Holder thereof by surrendering it, at the office of the Warrant Agent, or at the office of its successor
as Warrant Agent, together with (i) an election to purchase form, duly executed, electing to exercise such Warrants, as set forth
in the Warrant, and (ii) payment in full of the Warrant Price for each share of Common Stock as to which the Warrant is exercised
and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrants for the shares
of Common Stock and the issuance of such shares of Common Stock, as follows:

 

(a)       by
good certified check or good bank draft payable to the order of the Warrant Agent; or

 

(b)       in
the event of a redemption pursuant to Section 6 hereof in which the Company has elected to force all holders of Warrants to exercise
such Warrants on a “cashless basis,” by surrendering the Warrants for that number of shares of Common Stock equal
to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied
by the difference between the Warrant Price and the Fair Market Value (as defined below) by (y) the Fair Market Value. Solely
for purposes of this Section 3.3.1(b), the “Fair Market Value” shall mean the average last reported sale price of
the Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of Warrants pursuant to Section 6 hereof; or

 

(c)       with
respect to any Private Placement Warrants, so long as such Private Placement Warrants are held by the initial purchasers of the
Private Placement Warrants or their permitted transferees, by surrendering such Warrants for that number of shares of Common Stock
equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied
by the difference between the exercise price of the Warrants and the Fair Market Value (as defined below) by (y) the Fair Market
Value; provided, however, that no cashless exercise shall be permitted unless the Fair Market Value is equal to or higher than
the exercise price. Solely for purposes of this Section 3.3.1(c), the “Fair Market Value” shall mean the average last
reported sale price of the Common Stock for the ten (10) trading days ending on the third trading day prior to the date of exercise;
or

 

(d)       in
the event the registration statement required by Section 7.4 hereof is not effective and current within ninety (90) days after
the closing of the Business Combination, by surrendering such Warrants for that number of shares of the Common Stock equal to
the quotient obtained by dividing (x) the product of the number of the shares of Common Stock underlying the Warrants, multiplied
by the difference between the exercise price of the Warrants and the Fair Market Value (as defined below) by (y) the Fair Market
Value; provided, however, that no cashless exercise shall be permitted unless the Fair Market Value is equal to or higher than
the exercise price. Solely for purposes of this Section 3.3.1(d), the “Fair Market Value” shall mean the average reported
last sale price of the Common Stock for the ten (10) trading days ending on the day prior to the date of exercise.

 

     3

     

    

 

3.3.2        Issuance
of Certificates. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the
Warrant Price (if any), the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificate,
as applicable, for the number of shares of Common Stocker to which he is entitled, registered in such name or names as may be
directed by him, her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned
Warrant, as applicable, for the number of shares as to which such Warrant shall not have been exercised. Notwithstanding the foregoing,
in no event will the Company be required to net cash settle the Warrant exercise. No Warrant shall be exercisable and the Company
shall not be obligated to issue shares of Common Stock upon exercise of a Warrant unless the Common Stock issuable upon such Warrant
exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the Registered
Holder of the Warrants. In the event that the condition in the immediately preceding sentence is not satisfied with respect to
a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant and such Warrant may have no value and expire
worthless, in which case the purchaser of a Unit containing such Public Warrants shall have paid the full purchase price for the
Unit solely for the Common Stock underlying such Unit. Warrants may not be exercised by, or securities issued to, any Registered
Holder in any state in which such exercise would be unlawful.

 

3.3.3        Valid
Issuance. All Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly
issued, fully paid and nonassessable.

 

3.3.4        Date
of Issuance. Each person in whose name any such book-entry position or certificate, as applicable, for Common Stock is issued
shall for all purposes be deemed to have become the holder of record of such shares on the date on which the Warrant, or book-entry
position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery
of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when
the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have
become the holder of such shares at the close of business on the next succeeding date on which the share transfer books or book-entry
system are open.

 

3.3.5        Maximum
Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions
contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or
it makes such election. If the election is made by a holder, the Warrant Agent shall not affect the exercise of the holder’s
Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise,
such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially
own in excess of 4.9% or 9.8% (as specified by the Holder) (the “Maximum Percentage”) of the shares of Common Stock
outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of
shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of Common Stock
issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude
shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially
owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other
securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible
notes or convertible preference shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation
contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be
calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
For purposes of the Warrant, in determining the number of issued and outstanding shares of Common Stock, the holder may rely on
the number of issued and outstanding shares of Common Stock as reflected in (1) the Company’s most recent annual report
on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public filing with the Securities and Exchange
Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or
Continental Stock Transfer & Trust Company setting forth the number of shares of Common Stock outstanding. For any reason
at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally
and in writing to such holder the number shares of Common Stock then outstanding. In any case, the number of issued and outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity securities of the Company
by the holder and its affiliates since the date as of which such number of issued and outstanding shares of Common Stock was reported.
By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable
to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective
until the sixty-first (61st) day after such notice is delivered to the Company.

 

     4

     

    

 

3.4          No
Fractional Warrants or Shares. No fractional Warrants will be issued hereunder. Additionally, notwithstanding any provision
contained in this Warrant Agreement to the contrary, the Company shall not issue fractional shares of Common Stock upon the exercise
of Warrants. If the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest
in a share, the Company shall, upon such exercise, round down to the nearest whole number of shares of Common Stock to be issued
to such Warrant holder.

 

4.           Adjustments.

 

4.1          Share
Dividends - Split Ups. If, after the date hereof, and subject to the provisions of Section 4.5 below, the number of outstanding
shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a forward or reverse split of
shares of Common Stock, or other similar event, then, on the effective date of such stock dividend, split or similar event, the
number of shares of Common Stock issuable on exercise of each Warrant shall be increased or decreased in proportion to such increase
or decrease in outstanding shares of Common Stock. A rights offering to all holders of the shares of Common Stock entitling holders
to purchase shares of Common Stock at a price less than the Fair Market Value shall be deemed a stock dividend of a number of
shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering
(or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for the shares
of Common Stock) multiplied by (ii) one (1) minus the quotient of (x) the price per share of Common Stock paid in such rights
offering divided by (y) the Fair Market Value. For purposes of this subsection 4.1, if the rights offering is for securities convertible
into or exercisable for shares of Common Stock, in determining the price payable for the shares of Common Stock, there shall be
taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion.

 

4.2          Aggregation
of Shares. If, after the date hereof, and subject to the provisions of Section 4.6, the number of outstanding shares of Common
Stock is decreased by a consolidation, combination or reclassification of shares of Common Stock or other similar event, then,
on the effective date of such consolidation, combination, reclassification or similar event, the number of shares of Common Stock
issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock.

 

4.3          Extraordinary
Dividends. If the Company, at any time while the Warrants (or rights to purchase the Warrants) are outstanding and unexpired,
shall pay a dividend or make a distribution in cash, securities or other assets to the holders of the Common Stock on account
of such Common Stock (or other shares of the Company’s capital stock into which the Warrants are convertible), other than
(a) as described in subsection 4.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the conversion rights
of the holders of the Common Stock in connection with a proposed initial Business Combination, (d) as a result of the repurchase
of Common Stock by the Company in connection with an initial Business Combination or as otherwise permitted by the Investment
Management Trust Agreement between the Company and the Warrant Agent dated of even date herewith or (e) in connection with the
Company’s liquidation and the distribution of its assets upon its failure to consummate a Business Combination (any such
non-excluded event being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be decreased,
effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and the fair market value
(as determined by the Company’s board of directors, in good faith) of any securities or other assets paid on each share
of Common Stock in respect of such Extraordinary Dividend. For purposes of this subsection 4.3, “Ordinary Cash Dividends”
means any cash dividend or cash distribution which, when combined on a per share basis with the per share amounts of all other
cash dividends and cash distributions paid on the Common Stock during the 365-day period ending on the date of declaration of
such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this
Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number
of shares of Common Stock issuable on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Units
in the Offering).

 

     5

     

    

 

4.4          Adjustments
in Exercise Price. Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted,
as provided in Sections 4.1 and 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant
Price, immediately prior to such adjustment, by a fraction, (a) the numerator of which shall be the number of shares of Common
Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (b) the denominator of which shall
be the number of shares of Common Stock so purchasable immediately thereafter.

 

4.5         Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of Common
Stock (other than a change covered by Sections 4.1 or 4.2 hereof or one that solely affects the par value of such shares of Common
Stock), or, in the case of any merger or consolidation of the Company with or into another corporation (other than a consolidation
or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization
of the outstanding shares of Common Stock), or, in the case of any sale or conveyance to another corporation or entity of the
assets or other property of the Company as an entirety or substantially as an entirety, in connection with which the Company is
dissolved, the Registered Holders shall thereafter have the right to purchase and receive, upon the basis and upon the terms and
conditions specified in the Warrants and in lieu of the shares of Common Stock of the Company immediately theretofore purchasable
and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities
or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution
following any such sale or transfer, that the Registered Holder would have received if such Registered Holder had exercised his,
her or its Warrant(s) immediately prior to such event; and if any reclassification also results in a change in shares of Common
Stock covered by Sections 4.1 or 4.2, then such adjustment shall be made pursuant to Sections 4.1, 4.2, 4.3 and this Section 4.4.
The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations,
sales or other transfers.

 

4.6          Notices
of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise of a Warrant,
the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from
such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a
Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon
the occurrence of any event specified in Sections 4.1 – 4.5, the Company shall give written notice to each Registered Holder,
at the last address set forth for such Registered Holder in the Warrant Register, of the record date or the effective date of
the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

4.7          Notice
of Certain Transactions. In the event that the Company shall (a) offer to holders of all its Common Stock rights to subscribe
for or to purchase any securities convertible into shares of Common Stock or shares of stock of any class or any other securities,
rights or options, (b) issue any rights, options or warrants entitling all the holders of Common Stock to subscribe for shares
of Common Stock, or (c) make a tender offer, redemption offer or exchange offer with respect to the Common Stock, the Company
shall send to the Registered Holders a notice of such action or offer. Such notice shall be mailed to the Registered Holders at
their addresses as they appear in the Warrant Register, which shall specify the record date for the purposes of such dividend,
distribution or rights, or the date such issuance or event is to take place and the date of participation therein by the holders
of Common Stock, if any such date is to be fixed, and shall briefly indicate the effect of such action on the Common Stock and
on the number and kind of any other shares of stock and on other property, if any, and the number of shares of Common Stock and
other property, if any, issuable upon exercise of each Warrant and the Warrant Price after giving effect to any adjustment pursuant
to this Section 4 which would be required as a result of such action. Such notice shall be given as promptly as practicable after
the Company has taken any such action.

 

5.           Transfer
and Exchange of Warrants.

 

5.1          Registration
of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant
Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by
appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants
shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the
Warrant Agent to the Company from time to time upon request.

 

     6

     

    

 

5.2          Procedure
for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange
or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event
that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants), the Warrant
Agent shall not cancel such Warrant and issue new Warrants in exchange therefor until the Warrant Agent has received an opinion
of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive
legend.

 

5.3          Fractional
Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in
the issuance of a warrant certificate or book-entry position for a fraction of a Warrant, except as a part of the Units.

 

5.4          Service
Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

5.5          Warrant
Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the
terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever
required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

 

5.6          Private
Placement Warrants. The Warrant Agent shall not register any transfer of Private Placement Warrants until after the consummation
by the Company of an initial Business Combination, except for transfers (i) to the Company’s officers or directors, any
affiliates or family members of any of the Company’s officers or directors, any members or partners of the Sponsor or their
affiliates, or any affiliates of the Sponsor, (ii) in the case of an individual, by gift to a member of the individual’s
immediate family or to a trust, the beneficiary of which is a member of one of the individual’s immediate family, an affiliate
of such person or to a charitable organization, (iii) in the case of an individual, by virtue of laws of descent and distribution
upon death of the individual, (iv) in the case of an individual, pursuant to a qualified domestic relations order, (v) by private
sales or transfers made in connection with the Business Combination at prices no greater than the price at which the Private Placement
Warrants were originally purchased, (vi) by virtue of the holder’s organizational documents upon liquidation or dissolution
of the holder, (vii) to the Company for no value for cancellation in connection with the consummation of the Business Combination,
(viii) in the event of the Company’s liquidation prior to the completion of a Business Combination, or (ix) in the event
of completion of a liquidation, merger, share exchange or other similar transaction which results in all of the Company’s
shareholders having the right to exchange their share of Common Stock for cash, securities or other property subsequent to the
completion of a Business Combination, in each case (except for clause (vii) or with the prior written consent of the Company)
on the condition that prior to such registration for transfer, the Warrant Agent shall be presented with written documentation
pursuant to which each transferee or the trustee or legal guardian for such transferee (the “permitted transferees”)
agrees to be bound by the terms of the Private Placement Warrants Purchase Agreement.

 

6.            Redemption.

 

6.1          Redemption.
Subject to Section 6.4 hereof, all but not less than all of the outstanding Public Warrants may be redeemed, at the option of
the Company, at any time while they are exercisable and prior to their expiration (so long as there is a current registration
statement in effect with respect to the share of Common Stock underlying the Warrants), at the office of the Warrant Agent, upon
the notice referred to in Section 6.2, at the price of $0.01 per Warrant (“Redemption Price”), provided that the last
sales price of the Common Stock equals or exceeds $16.50 per share (subject to adjustment in accordance with Section 4 hereof),
on each of twenty (20) trading days within any thirty (30) trading day period ending on the third business day prior to the date
on which notice of redemption is given.

 

     7

     

    

 

6.2          Date
Fixed for, and Notice of, Redemption. In the event that the Company shall elect to redeem all of the Public Warrants, the
Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed by first
class mail, postage prepaid, by the Company not less than 30 days prior to the Redemption Date to the registered holders of the
Public Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the
manner herein provided shall be conclusively presumed to have been duly given whether or not the registered holder received such
notice.

 

6.3          Exercise
After Notice of Redemption. The Public Warrants may be exercised, for cash (or on a “cashless basis” in accordance
with Section 3 hereof) at any time after notice of redemption shall have been given by the Company pursuant to Section 6.2 hereof
and prior to the Redemption Date. In the event that the Company determines to require all holders of Public Warrants to exercise
their Warrants on a “cashless basis” pursuant to Section 3.3.1(b), the notice of redemption will contain the information
necessary to calculate the number of shares of Common Stock to be received upon exercise of the Warrants, including the Fair Market
Value in such case. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to
receive, upon surrender of the Warrants, the Redemption Price.

 

6.4          Exclusion
of Private Placement Warrants. The Company agrees that the redemption rights provided in this Section 6 shall not apply to
the Private Placement Warrants if at the time of the redemption such Private Placement Warrants continue to be held by the initial
purchasers or their permitted transferees. However, once such Private Placement Warrants are transferred (other than to permitted
transferees under Section 5.6), the Company may redeem the Private Placement Warrants, provided that the criteria for redemption
are met, including the opportunity of the holder of such Private Placement Warrants to exercise the Private Placement Warrants
prior to redemption pursuant to Section 6.3. Private Placement Warrants that are transferred to persons other than Permitted Transferees
shall upon such transfer cease to be Private Placement Warrants and shall become Public Warrants under this Agreement.

 

7.            Other
Provisions Relating to Rights of Holders of Warrants.

 

7.1          No
Rights as Shareholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the
Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights
to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors
of the Company or any other matter.

 

7.2         Lost,
Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant
Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen,
mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or
not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3          Reservation
of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares
of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

7.4          Registration
of Common Stock. The Company agrees that, as soon as practicable, but in no event later than twenty (20) Business Days after
the closing of its initial Business Combination, it shall use its reasonable best efforts to file with the Securities and Exchange
Commission a registration statement for the registration, under the Act, of the Common Stock issuable upon exercise of the Warrants,
and it shall use its reasonable best efforts to take such action as is necessary to register or qualify for sale, in those states
in which the Warrants were initially offered by the Company, the Common Stock issuable upon exercise of the Warrants, to the extent
an exemption is not available. The Company will use its reasonable best efforts to cause the same to become effective and to maintain
the effectiveness of such registration statement until the expiration of the Warrants in accordance with the provisions of this
Agreement. In addition, the Company agrees to use its reasonable best efforts to register such securities under the blue sky laws
of the states of residence of the exercising warrant holders to the extent an exemption is not available. If any such registration
statement has not been declared effective by the 90th day following the closing of the Business Combination, holders of the Warrants
shall have the right, during the period beginning on the 91st day after the closing of the Business Combination and ending upon
such registration statement being declared effective by the Securities and Exchange Commission, and during any other period when
the Company shall fail to have maintained an effective registration statement covering the Common Stock issuable upon exercise
of the Warrants, to exercise such Warrants on a “cashless basis” as determined in accordance with Section 3.3.1(d).
The Company shall provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with
securities law experience) stating that (i) the exercise of the Warrants on a cashless basis in accordance with this Section 7.4
is not required to be registered under the Act and (ii) the Common Stock issued upon such exercise are transferable without registration
under the Act by any holder which (a) is not an “affiliate” of the Company as defined in Rule 144(a)(1) under the
Securities Act, (b) has not been such an “affiliate” within three months of such transfer, (c) has not acquired such
share of Common Stock within one year of such transfer, and (iii) will not be required to bear a restrictive legend. For the avoidance
of any doubt, unless and until all of the Warrants have been exercised on a cashless basis or have expired, the Company shall
continue to be obligated to comply with its registration obligations under the first three sentences of this Section 7.4.

 

     8

     

    

 

8.            Concerning
the Warrant Agent and Other Matters.

 

8.1          Payment
of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the
Warrant Agent in respect of the issuance or delivery of share of Common Stock upon the exercise of Warrants, but the Company shall
not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

8.2          Resignation,
Consolidation, or Merger of Warrant Agent.

 

8.2.1        Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the
office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of
30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant
(who shall, with such notice, submit his Warrant for inspection by the Company), then the holder of any Warrant may apply to the
Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s
cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing
under the laws of the State of New York, in good standing, and authorized under such laws to exercise corporate trust powers and
subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested
with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect
as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary
or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring
to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request
of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for
more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities,
duties, and obligations.

 

8.2.2        Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.

 

8.2.3        Merger
or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor
Warrant Agent under this Agreement without any further act.

 

     9

     

    

 

8.3          Fees
and Expenses of Warrant Agent.

 

8.3.1        Remuneration.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and will
reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its
duties hereunder.

 

8.3.2        Further
Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged,
and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent
for the carrying out or performing of the provisions of this Agreement.

 

8.4         Liability
of Warrant Agent.

 

8.4.1        Reliance
on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary
or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a statement signed by the Chief Executive Officer or Chairman of the Board of Directors of the Company
and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith
by it pursuant to the provisions of this Agreement.

 

8.4.2        Indemnity.
The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees
to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable,
documented counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement except as a result
of the Warrant Agent’s gross negligence, willful misconduct, or bad faith.

 

8.4.3        Exclusions.
The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity
or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of
any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to make any adjustments required
under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining
of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation
or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any
Warrant or as to whether any shares of Common Stock will, when issued, be valid and fully paid and nonassessable.

 

8.5         Acceptance
of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the
terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised
and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of Common Stock
through the exercise of Warrants.

 

9.            Miscellaneous
Provisions.

 

9.1          Successors.
All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure
to the benefit of their respective successors and assigns.

 

9.2          Notices.
Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any
Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified
mail or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address
is filed in writing by the Company with the Warrant Agent), as follows:

 

Health
Sciences Acquisitions Corporation

412 West 15th Street, Floor 9

New York, New York 10011

Attn: Alice Lee, Secretary

 

     10

     

    

 

Any
notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to
or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified
mail or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address
is filed in writing by the Warrant Agent with the Company), as follows:

 

Continental
Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

Attn: Compliance Department

 

with
a copy in each case to:

 

Loeb & Loeb LLP

345 Park Avenue

New York, New York 10154

Attn: Giovanni Caruso, Esq.

 

Kirkland
& Ellis LLP

601 Lexington Avenue

New York, New York 10022

Attn: Christian O. Nagler

 

and

Chardan Capital Markets LLC

17 State Street

New York, New York 10004

 

9.3          Applicable
Law. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all respects
by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application
of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising
out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United
States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or
certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.2 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim.

 

9.4         Persons
Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions
hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto
and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Warrant Agreement or of any
covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements
contained in this Warrant Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and
assigns and of the Registered Holders of the Warrants.

 

     11

     

    

 

9.5          Examination
of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant
Agent in the United States, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder
to submit his Warrant for inspection by it.

 

9.6          Counterparts.
This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.7          Effect
of Headings. The Section headings herein are for convenience only and are not part of this Warrant Agreement and shall not
affect the interpretation thereof.

 

9.8          Amendments.

 

This Warrant Agreement and any Warrant certificate may be amended by the parties hereto by executing a supplemental warrant agreement
(a “Supplemental Agreement”), without the consent of any of the Warrant Holders, for the purpose of (i) curing any
ambiguity, or curing, correcting or supplementing any defective provision contained herein, or making any other provisions with
respect to matters or questions arising under this Warrant Agreement that is not inconsistent with the provisions of this Warrant
Agreement or the Warrant certificates, (ii) evidencing the succession of another corporation to the Company and the assumption
by any such successor of the covenants of the Company contained in this Warrant Agreement and the Warrants, (iii) evidencing and
providing for the acceptance of appointment by a successor Warrant Agent with respect to the Warrants, (iv) adding to the covenants
of the Company for the benefit of the Registered Holders or surrendering any right or power conferred upon the Company under this
Warrant Agreement, or (viii) amending this Warrant Agreement and the Warrants in any manner that the Company may deem to be necessary
or desirable and that will not adversely affect the interests of the Registered Holders in any material respect. All other modifications
or amendments to this Warrant Agreement, including any amendment to increase the Warrant Price or shorten the Exercise Period,
shall require the written consent of the Registered Holders of a majority of the then outstanding Warrants. Notwithstanding the
foregoing, the Company may extend the duration of the Exercise Period in accordance with Section 3.2 without such consent.

 

9.9          Trust
Account Waiver. The Warrant Agent acknowledges and agrees that it shall not make any claims or proceed against the trust account
established by the Company in connection with the Public Offering (as more fully described in the Registration Statement) (“Trust
Account”), including by way of set-off, and shall not be entitled to any funds in the Trust Account under any circumstance.
In the event that the Warrant Agent has a claim against the Company under this Agreement, the Warrant Agent will pursue such claim
solely against the Company and not against the property held in the Trust Account.

 

9.10        Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Warrant Agreement or of any other term or provision hereof. Furthermore, in lieu of any
such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement
a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[Signature
Page Follows]

 

     12

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	HEALTH
    SCIENCES ACQUISITIONS CORPORATION
	 	 	 
	 	By:	/s/
    Roderick Wong
	 	 	Name: Roderick Wong,
    MD
	 	 	Title:
        Chief Executive Officer

         

	 	 	 
	 	CONTINENTAL
    STOCK TRANSFER & TRUST COMPANY
	 	 	 
	 	By:	/s/
    Erika Young
	 	 	Name: Erika Young
	 	 	Title: Vice President

 

[Signature
Page to the Warrant Agreement]

 

     

    

    

 

EXHIBIT
A

 

	NUMBER	 	(SEE
    REVERSE SIDE FOR LEGEND)	 	WARRANTS

THIS
WARRANT WILL BE VOID IF NOT EXERCISED

PRIOR
TO

THE
EXPIRATION DATE (DEFINED BELOW)

 

HEALTH
SCIENCES ACQUISITIONS CORPORATION

 

CUSIP
42227C 110

 

WARRANT

 

THIS
CERTIFIES THAT, for value received

 

is
the registered holder of a warrant or warrants (the “Warrant(s)”) to purchase one half of one fully paid and non-assessable
share of Common Stock, par value $0.0001 per share (“Shares”), of Health Sciences Acquisitions Corporation, a Delaware
corporation (the “Company”), expiring at 5:00 p.m., New York City time, on the five year anniversary (the “Expiration
Date”) of the completion by the Company of a merger, share exchange, asset acquisition, stock purchase, recapitalization,
reorganization or other similar business combination with one or more businesses or entities (a “Business Combination”).
The Warrant entitles the holder thereof to purchase from the Company, commencing on the later of (i) 30 days after the Company’s
completion of a Business Combination and (ii) twelve (12) months from the closing of the Company’s initial public offering,
such number of Shares of the Company at the price of $11.50 per share, upon surrender of this Warrant Certificate and payment
of the Warrant Price at the office or agency of the Warrant Agent, Continental Stock Transfer & Trust Company, but only subject
to the conditions set forth herein and in the Warrant Agreement between the Company and Continental Stock Transfer & Trust
Company. In no event will the Company be required to net cash settle the warrant exercise. The Warrant Agreement provides that
upon the occurrence of certain events the Warrant Price and the number of Warrant Shares purchasable hereunder, set forth on the
face hereof, may, subject to certain conditions, be adjusted. The term Warrant Price as used in this Warrant Certificate refers
to the price per Share at which Shares may be purchased at the time the Warrant is exercised.

 

No
fraction of a Share will be issued upon any exercise of a Warrant. If the holder of a Warrant would be entitled to receive a fraction
of a Share upon any exercise of a Warrant, the Company shall, upon such exercise, round down to the nearest whole number the number
of Shares to be issued to such holder.

 

Upon
any exercise of the Warrant for less than the total number of full Shares provided for herein, there shall be issued to the registered
holder hereof or the registered holder’s assignee a new Warrant Certificate covering the number of Shares for which the
Warrant has not been exercised.

 

Warrant
Certificates, when surrendered at the office or agency of the Warrant Agent by the registered holder hereof in person or by attorney
duly authorized in writing, may be exchanged in the manner and subject to the limitations provided in the Warrant Agreement, but
without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor and evidencing in
the aggregate a like number of Warrants.

 

Upon
due presentment for registration of transfer of the Warrant Certificate at the office or agency of the Warrant Agent, a new Warrant
Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to
the transferee in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without
charge except for any applicable tax or other governmental charge.

 

     

    

    

 

The
Company and the Warrant Agent may deem and treat the registered holder as the absolute owner of this Warrant Certificate (notwithstanding
any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution
to the registered holder, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice
to the contrary.

 

This
Warrant does not entitle the registered holder to any of the rights of a stockholder of the Company.

 

The
Company reserves the right to call the Warrant at any time prior to its exercise, with a notice of call in writing to the holders
of record of the Warrant, giving 30 days’ notice of such call at any time after the Warrant becomes exercisable if the last
sale price of the Shares has been at least $16.50 per share for any 20 trading days within a 30 trading day period ending on the
third business day prior to the date on which notice of such call is given, if, and only if, there is a current registration statement
in effect with respect to the Shares underlying the Warrant. The call price of the Warrants is to be $0.01 per Warrant. Any Warrant
either not exercised or tendered back to the Company by the end of the date specified in the notice of call shall be canceled
on the books of the Company and have no further value except for the $0.01 call price.

 

	 	 	 	 
	 	 	 	 
	By	 	 	 
	 	Chief
    Executive Officer	 	Chairman
    of the Board

 

     

    

    

 

SUBSCRIPTION
FORM

 

To
Be Executed by the Registered Holder in Order to Exercise Warrants

 

The
undersigned Registered Holder irrevocably elects to exercise Warrants represented by this Warrant Certificate, and to purchase
the shares of Common Stock issuable upon the exercise of such Warrants, and requests that Certificates for such shares shall be
issued in the name of

	(PLEASE
    TYPE OR PRINT NAME AND ADDRESS)
	(SOCIAL
    SECURITY OR TAX IDENTIFICATION NUMBER)

	and be
    delivered to	 
	 	(PLEASE
    PRINT OR TYPE NAME AND ADDRESS)

 

and,
if such number of Warrants shall not be all the Warrants evidenced by this Warrant Certificate, that a new Warrant Certificate
for the balance of such Warrants be registered in the name of, and delivered to, the Registered Holder at the address stated below:

	Dated:	 	 	(SIGNATURE)	 
	 	 	 	(ADDRESS)	 
	 	 	 	(TAX
    IDENTIFICATION NUMBER)	 

 

     

    

    

 

ASSIGNMENT

 

To
Be Executed by the Registered Holder in Order to Assign Warrants

 

For
Value Received, _________ hereby sell, assign, and transfer unto

 

	(PLEASE
    TYPE OR PRINT NAME AND ADDRESS)
	(SOCIAL
    SECURITY OR TAX IDENTIFICATION NUMBER)

	and
    be delivered to	 
	 	(PLEASE
    PRINT OR TYPE NAME AND ADDRESS)

 

_________________________of
the Warrants represented by this Warrant Certificate, and hereby irrevocably constitute and appoint _______________________
Attorney to transfer this Warrant Certificate on the books of the Company, with full power of substitution in the
premises.

 

	Dated:	 	 	 	 
	 	 	 	(SIGNATURE)	 

 

THE
SIGNATURE TO THE ASSIGNMENT OF THE SUBSCRIPTION FORM MUST CORRESPOND TO THE NAME WRITTEN UPON THE FACE OF THIS WARRANT CERTIFICATE
IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A COMMERCIAL BANK OR
TRUST COMPANY OR A MEMBER FIRM OF THE AMERICAN STOCK EXCHANGE, NEW YORK STOCK EXCHANGE, PACIFIC STOCK EXCHANGE OR CHICAGO STOCK
EXCHANGE.

 

     

    

    

 

EXHIBIT
B

 

LEGEND

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT
TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG HEALTH SCIENCES ACQUISITIONS CORPORATION
(THE “COMPANY”), HEALTH SCIENCES HOLDINGS, LLC AND THE OTHER INDIVIDUALS PARTY THERETO, THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY
COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED
TRANSFEREE (AS DEFINED IN SECTION 5 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER
PROVISIONS.

 

SECURITIES
EVIDENCED BY THIS CERTIFICATE AND COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION
RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.

 

    B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]